A Nonenhancing World Health Organization Grade II Intramedullary Spinal Ependymoma in the Conus: Case Illustration and Review of Imaging Characteristics

Andrew A. Fanous1 Gregory F. Jost2 Meic H. Schmidt2

1 Department of Neurosurgery, School of Medicine and Biomedical Science, University at Buffalo, State University of New York, Buffalo, New York
2 Department of Neurosurgery, University of Utah, Salt Lake City, Utah

Address for correspondence and reprint requests Meic H. Schmidt, M.D., Department of Neurosurgery, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT 84132 (e-mail: meic.schmidt@hsc.utah.edu).

Global Spine J 2012;2:57–64.

Abstract

Spinal ependymomas comprise ~60% of all intramedullary tumors in adults. Ependymomas demonstrate distinct imaging features, such as central location within the spinal cord, symmetrical expansion, intra- and extratumoral cysts, hemosiderin caps, and strong enhancement on contrast-injected, T1-weighted magnetic resonance (MR) imaging. In adults, most ependymomas are myxopapillary, and in children, most are nonmyxopapillary. In general, nonmyxopapillary or classic ependymomas are hyperintense on T2- and hypointense on T1-weighted MR imaging, but whereas the signal intensity on T1 and T2 is variable, homogeneous contrast enhancement is usually a characteristic finding. Here, the authors provide an overview on spinal ependymomas with an emphasis on imaging characteristics and morphological background and present the case of a World Health Organization grade II ependymoma in the conus that did not enhance. Interestingly, the tumor contained a large hemorrhagic cyst. Just as hemorrhagic metastatic tumors may not enhance, a hemorrhagic ependymoma may likewise not enhance after administration of contrast agent. Thus, the differential diagnosis of a nonenhancing intramedullary lesion in the conus should include ependymoma, particularly if there is concomitant hemorrhage.

Keywords
► intramedullary
► spinal cord
► tumor
► ependymoma
► MR imaging

Ependymomas are the most common intramedullary spinal cord tumors in adults. They can be broadly grouped as either myxopapillary ependymomas or classic nonmyxopapillary ependymomas. Spinal ependymomas have characteristic features that can be observed both radiologically and grossly, including cystic components and hemorrhagic elements with hemosiderin caps. Moreover, spinal ependymomas almost always exhibit strong contrast enhancement on magnetic resonance (MR) imaging, with a sharp margin of enhancement around the tumor margin. The authors review histopathologic, clinical, and radiographic characteristics of spinal ependymomas and report a case of nonenhancing classic nonmyxopapillary intramedullary spinal ependymoma, which likely represents the first description in the literature of a histologically proven nonmyxopapillary ependymoma that failed to enhance after administration of intravenous contrast agent.

Case Report

History and Presentation
The patient is a 27-year-old woman who presented with a 4-year history of progressively worsening low back pain, which radiated to the buttocks and occasionally into the right leg and foot. The pain was exacerbated by activity, and rest provided mild relief. The patient also complained of bilateral...
lower extremity numbness and increasing urinary frequency. Findings on her neurological examination were normal except for absent deep tendon reflexes in the lower extremities. MR imaging of the lumbar spine revealed a complex, 17 × 73-mm, nonenhancing cystic mass at the level of the conus extending from the superior aspect of T12 to the midlevel of the L2 vertebral body. T2-weighted MR imaging showed a fluid/fluid level, consistent with a hemorrhagic component, and large amounts of intracystic hemosiderin deposits. There was minimal septal and peripheral enhancement in the lesion, with no evidence of enhancement anywhere else in the lesion (►Fig. 1). An associated hydrosyringomyelia in the lower thoracic region, mild posterior wall scalloping of the T12 and L1 vertebral bodies, and mild kyphosis suggested a long-standing process (►Fig. 2).

**Surgery**

An open biopsy and potential resection of the lesion was recommended to the patient. The lesion was approached via en bloc removal of the laminae T10 to L1 and a partial laminectomy of L2 to expose the spinal canal along the entire pathological area including the cephalad cyst and to find normal spinal cord rostral to the lesion. After the thecal sac and arachnoid were opened, large amounts of hemosiderin and hemorrhage were seen (►Fig. 3). The filum terminale was identified using electrical stimulation, cauterized, and sectioned. The conus-expanding cyst was completely drained, and deep to the cyst, biopsies from the solid portion of the tumor were obtained. Because intraoperative frozen sections displayed small blue cells consistent with lymphoma, proceeding with an aggressive resection was not indicated as it could potentially aggravate or cause new neurological deficits. Thus, the dura was closed after partial resection of ~30% of the lesion. The T10 to L1 laminae were replaced and fixed with cranial microplates.

**Pathological Analysis**

Histopathologic analysis revealed evidence of rosettes and perivascular pseudorosettes on hematoxylin and eosin-stained slides (►Fig. 4). The tumor cells showed heterogeneous positive staining for glial fibrillary acidic protein and S-100 markers, as well as focal apical membranous and intracytoplasmic punctate staining for epithelial membrane antigen (►Fig. 4). The tumor cells were negative for Melan A and HMB45 markers. In addition, marked piloid gliosis and deposits of hemosiderin pigment were present. The final
Histopathologic samples of the tumor showed rosettes (A, arrows) and perivascular pseudorosettes (B, arrow) on hematoxylin and eosin–stained slides. The tumor was strongly positive for glial fibrillary acidic protein (C) and focally positive for epithelial membrane antigen (D). The diagnosis was ependymoma.

**Figure 2** Radiograph showing mild posterior wall scalloping of T12 and L1 (arrows) suggesting a long-standing process.

**Figure 3** Intraoperative photograph showing the surgical site after the thecal sac and arachnoid were opened. Large amounts of hemosiderin are seen upon entering the tumor in the conus.

**Figure 4** Histopathologic samples of the tumor showed rosettes (A, arrows) and perivascular pseudorosettes (B, arrow) on hematoxylin and eosin–stained slides. The tumor was strongly positive for glial fibrillary acidic protein (C) and focally positive for epithelial membrane antigen (D). The diagnosis was ependymoma.
diagnosis was ependymoma World Health Organization (WHO) grade II.

**Follow-up**
The patient elected to proceed with observation of the lesion by regular MR imaging scans. At 6-month follow-up, the lesion had slightly decreased in size, and the patient had not experienced any new neurological deficits (*Fig. 5*).

**Discussion**

**Clinical Overview of Spinal Cord Ependymomas**

Intramedullary spinal cord tumors account for 4 to 10% of all central nervous system (CNS) tumors.1 The most common intramedullary spinal cord tumors in adults are ependymomas, comprising ~60% of all such tumors.1-4 In the pediatric population, ependymomas are the second most common intramedullary spinal tumors after astrocytomas, constituting ~30% of all pediatric intramedullary spinal lesions.5

Ependymomas are benign, slow-growing tumors6 that can arise anywhere in the neuraxis. They originate from ependymal cells that line the cerebral ventricles and the spinal canal. Hence, they normally occupy a central location within the spinal cord and expand symmetrically, which can cause interruption of spinothalamic tracts.1 This is useful in differentiating them from the infiltrating asymmetric appearance of astrocytomas. Intramedullary spinal ependymomas are occasionally associated with neurofibromatosis type 2.1

Spinal ependymomas exhibit a bimodal age distribution, with peaking incidences in the third and sixth decades, and with a mean age of diagnosis around 38.3 years of age.1 There is a slight male predominance (between 54% and 58%).1,7 The clinical symptoms of spinal ependymomas are usually mild, leading to delay in diagnosis. The mean duration of symptoms prior to diagnosis is 36.5 months.1 The most common symptoms associated with intramedullary spinal ependymomas include back or neck pain (67%), sensory deficits (52%), motor weakness (46%), and bowel or bladder dysfunction (15%).1

Prognosis depends on the preoperative neurological status, the grade and histological type of the tumor, the comprehensiveness of the surgical resection, and the evidence of dissemination.8,9 Although spinal ependymomas lack a capsule, it is generally possible to develop a clear plane between the tumor and spinal cord and achieve a complete resection.4,7,10,11 Shorter duration of symptoms usually correlates with better postoperative outcome.12 The 5-year rate of survival is ~82%.1 Postoperative radiotherapy after complete resection does not prolong survival.8,11 It is reserved for recurrent disease or lesions that undergo subtotal resection,10,12-14 both of which may also be considered for revision surgery.15

![Figure 5](image-url) X-ray and magnetic resonance images at 6 months’ follow-up. Sagittal alignment is conserved (A). Magnetic resonance images (B and C) shows the partially resected tumor. A slight decrease in size and subtotal involution of the cephalad cyst is noted.
Histopathologic and WHO Classification of Spinal Ependymomas

Histopathologically, spinal ependymomas usually appear as uniform cells with moderately hyperchromic nuclei. There are five different histopathologic types of spinal ependymomas, namely cellular, tanycytic, epithelial, papillary, and myxopapillary. The most common histological subtype of spinal ependymomas is the cellular type. These are made of either cuboidal cells or low columnar cells and are characterized by the presence of perivascular pseudorosette formation, in which the neoplastic ependymal cells are distributed in a ring fashion around blood vessels. Tanycytic ependymomas comprise elongated cells similar to the cells seen in astrocytomas. Epithelial ependymomas are composed of either linear or glandular arrangements of cells that form true ependymal rosettes. Papillary ependymomas are rare and are histologically similar to choroid plexus papilloma. Myxopapillary ependymomas arise almost exclusively from the filum terminale and represent 30% of all spinal ependymomas. Myxopapillary ependymomas are distinguished by their intracellular and perivascular accumulation of mucin. In fact, myxopapillary ependymoma is the only histological subtype of spinal ependymomas that can be distinguished based on neuroimaging.

According to the WHO grading system, ependymomas can be broadly classified into one of three different categories. WHO grade I tumors are either subependymomas or myxopapillary ependymomas. WHO grade II lesions are low-grade, nonanaplastic tumors, and WHO grade III ependymomas exhibit anaplastic features and mitotic figures. Overall, about half of intramedullary spinal cord ependymomas are classic ependymomas (mainly WHO grade II), and the other half are of the myxopapillary type (WHO grade I), although this distribution varies with age. In adults, most spinal ependymomas are of the myxopapillary type (WHO grade I), which occur almost exclusively at the filum terminale and within the conus or the cauda equina (†Fig. 6). On the other hand, pediatric spinal ependymomas are more commonly classic nonanaplastic ependymomas (WHO grade II).

The location of spinal cord ependymomas usually correlates with their WHO grade. For instance, classic spinal cord ependymomas are most common in the cervical region (67%; †Fig. 7), followed by the thoracic region (49%), distal cord, and the conus medullaris (6.5%). On the other hand, myxopapillary ependymomas (WHO grade I) are the most common type of primary tumors in the lower cord, conus, cauda equina, and filum terminale.

Cystic Components in Intramedullary Spinal Ependymomas

Between 50% and 85% of spinal ependymomas are associated with cystic components. These cysts may be either...
intratumoral, rostral to the lesion, or caudal to it (Fig. 1 and 7). More than one type of cystic change may exist in the same patient: Intratumoral cysts are also known as true tumoral cysts and occur in 24% of all cases of intramedullary spinal ependymomas (Fig. 1 and 7). They are thought to be secondary to degeneration, necrosis, and liquefaction within the lesion itself and administration of contrast agent results in peripheral rim enhancement around the cyst. Cysts of the central canal are thought to be caused by reactive dilation at the rostral or caudal pole of the tumor (polar or satellite cysts) or obstruction of the central canal. These occur in 62% of all cases of intramedullary spinal ependymomas and do not enhance (syringomyelia; Fig. 7). Intratumoral cysts—the only cystic changes with peripheral enhancement after administration of contrast material—must be distinguished from the other two types of cystic changes because they must be included in the excision in light of the fact that they may be lined with abnormal tumorigenic glial cells. In tumors associated with rostral/caudal cysts, only the solid lesion needs to be resected, and the cysts may be drained or aspirated during surgery. Secondary reactive cysts tend to resolve on their own after excision of the tumor. Moreover, ~60% of spinal ependymomas are associated with cord edema.

**Hemorrhage in Intramedullary Spinal Ependymomas**

Hemorrhage is a common finding in spinal ependymomas, and the presence of a hemosiderin cap is considered almost pathognomonic for these tumors. This hemosiderin cap appears as a “cap sign” on T1- and T2-weighted MR images as a rim of extreme hypointensity along the tumor margin at the interface between the tumor and the spinal cord (Fig. 1). Between 20% and 33% of all spinal ependymomas are associated with this cap sign. In certain cases, spinal ependymomas can result in subarachnoid hemorrhage. In one study of 26 spinal ependymomas conducted by Kahan et al, ~20% of all lesions demonstrated evidence of chronic hemorrhage on MR imaging. The pathophysiology behind hemorrhage in spinal ependymomas remains a topic of debate. Some authors attribute it to the high vascularity of the tumor, and others attribute it to the interface between the ependymoma and the normal cord that is vulnerable to bleeding.

**Neuroimaging of Intramedullary Spinal Ependymomas**

On neuroimaging, spinal ependymomas usually span three to four vertebral segments, although the involvement of as many as 15 segments has been reported. In ~10% of cases, MR imaging demonstrates evidence of long-standing tumor lesions, evidenced by the presence of bone remodeling, scoliosis, erosion of the medial aspect of the pedicles, laminar thinning, and scalloping of the posterior vertebral bodies. These osseous changes are most commonly caused by ependymomas arising at the lumbar and lumbosacral spine.

The two main imaging modalities used for the assessment of spinal ependymomas are computed tomography (CT) and MR imaging, the latter being the imaging modality of choice. CT has the advantage of demonstrating subtle foci of calcification within the tumor, which is particularly useful in intracranial ependymomas, but calcification is uncommon in spinal ependymomas. MR imaging is superior in defining the size and properties of the lesion. Moreover, MR imaging is more sensitive than CT in the detection of leptomeningeal spread and in the characterization of associated structural...
abnormalities such as cysts, hemorrhage, or edema.\textsuperscript{1,32} Classic nonmyxopapillary spinal ependymomas usually demonstrate high T2 signal intensity and low T1 signal intensity (\textsuperscript{\textbullet} Fig. 7)\textsuperscript{5,7,21,31}; however, \textsim\textasciitilde20\% of spinal ependymomas demonstrate low T2 signal, which is suggestive of isolated hemorrhage.\textsuperscript{34} Moreover, a significant percentage of myxo-papillary ependymomas are hyperintense on both T1- and T2-weighted images, likely because of the presence of a significant amount of mucin (\textsuperscript{\textbullet} Fig. 6).\textsuperscript{7,18,23,33}

**Contrast Enhancement in Intramedullary Spinal Ependymomas**

Contrast-enhanced MR imaging has been used as a diagnostic tool since 1984\textsuperscript{25} and was first employed for the diagnosis of intraspinal tumors in 1985.\textsuperscript{36} For a long time, enhancing intramedullary spinal lesions were considered tumorigenic until proven otherwise, and nonenhancing lesions were consequently considered benign.\textsuperscript{22,36–38} In fact, contrast enhancement has been demonstrated in all types of spinal cord neoplasms, regardless of the grade or the degree of invasiveness.\textsuperscript{25} Contrast enhancement has been ascribed to the actively dividing nature of these tumors, and it has been hypothesized that the invasive nature of malignant tumors results in fenestration of the endothelium and subsequent leakage of contrast material into the extravascular space.\textsuperscript{1,25} It is well accepted that spinal ependymomas almost always enhance intensely after administration of intravenous contrast material.\textsuperscript{1,3,5,7,10,33,39–41} For instance, in a study of seven intramedullary spinal ependymomas of all WHO grades conducted by Parizel et al.,\textsuperscript{37} all seven ependymomas demonstrated complete contrast enhancement after administration of contrast material. In addition to their overall contrast enhancement, spinal ependymomas usually demonstrate a sharp margin of enhancement around the tumor margin.\textsuperscript{10,34}

Here we report the rare case of a nonenhancing spinal cord ependymoma, which was histologically proven to be a WHO grade II lesion. Although some have suggested that the absence of contrast enhancement does not necessarily exclude the possibility of intramedullary neoplastic lesions,\textsuperscript{24} only a few authors have reported cases of histologically proven nonenhancing spinal tumors.\textsuperscript{42} Failure to enhance after contrast administration seems to be a characteristic of tumors associated with significant hemorrhagic components. For instance, although metastatic tumors of the CNS almost always exhibit contrast enhancement,\textsuperscript{43} this enhancement is occasionally minimal to absent in metastatic CNS tumors associated with significant hemorrhage.\textsuperscript{44,45} In addition to hemorrhage, some authors have suggested that the isolated nature of certain tumors results in a pattern of minimal to no enhancement on MR imaging.\textsuperscript{44} In a study of 130 intramedullary spinal cord tumors, White et al.\textsuperscript{25} found 11 cases (9\%) that failed to enhance. Eight of these nonenhancing tumors were astrocytomas, and one was a subependymoma. The series comprised 83 ependymomas, all of which showed full enhancement pattern. In fact, one of the most well-established radiological features of spinal ependymomas is their ability to exhibit intense homogenous enhancement on postcontrast MR imaging.\textsuperscript{1–3,5,7,10,33,39–41} Only rarely does one find cases in the literature of spinal ependymomas with minimal to no enhancement. For instance, out of 16 spinal ependymomas reported by Kahan et al.,\textsuperscript{7} 3 (19\%) demonstrated only rim enhancement, 1 (6\%) demonstrated minimal enhancement, and 1 (6\%) demonstrated no enhancement at all. The nonenhancing lesion was a myxopapillary ependymoma, and the histopathologic type and WHO grade of the minimally enhancing and only rim-enhancing lesions were not reported. More than a decade later, such cases of spinal ependymomas with abnormal patterns of enhancement remain poorly documented in the literature. Our present case report likely represents the first report in the literature of a histologically proven nonmyxopapillary ependymoma that failed to enhance after administration of intravenous contrast.

**Conclusion**

Spinal ependymomas are the most frequent intramedullary tumor in adults. In general, complete removal of these surgically amenable lesions should be attempted as this improves prognosis. Spinal ependymomas demonstrate distinct imaging features, such as intra- and extratumoral cysts, hemosiderin caps, and strong enhancement of the solid tumor portion, which aid to establish a preliminary preoperative diagnosis. Nevertheless, our illustrated case report suggests that lack of enhancement after administration of contrast agent does not preclude the diagnosis of a spinal ependymoma, particularly when the imaging study reveals hemorrhage into the tumor.

**Acknowledgments**

We thank Kristin Kraus, M.Sc., for editorial assistance with this paper.

**Disclosures**

Andrew A. Fanous, None
Gregory F. Jost, None
Meic H. Schmidt, None

**References**

1. Koeller KK, Rosenblum RS, Morrison AL. Neoplasms of the spinal cord and filum terminale: radiologic-pathologic correlation. Radiographics 2000;20:1721–1749
2. Balériaux DL. Spinal cord tumors. Eur Radiol 1999;9:1252–1258
3. Ferrante I, Mastronardi L, Celli P, Lunardi P, Acqui M, Fortuna A. Intramedullary spinal cord ependymomas—a study of 45 cases with long-term follow-up. Acta Neurochir (Wien) 1992;119:74–79
4. Sharma MC, Ghara N, Jain D, Sarkar C, Singh M, Mehta VS. A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas. Neuropathology 2009;29:148–155
5. Yuh EL, Barkovich AJ, Gupta N. Imaging of ependymomas: MRI and CT. Childs Nerv Syst 2009;25:1203–1213
Global Spine Journal Vol. 2 No. 1/2012

A Nonenhancing Grade II Intramedullary Ependymoma

Fanous et al.

Rudá R, Gilbert M, Soffietti R. Ependymomas of the adult: molecular biology and treatment. Curr Opin Neurol 2008;21:754–761

Kahan H, Sklar EM, Post MJ, Bruce JH. MR characteristics of histopathologic subtypes of spinal ependymoma. AJNR Am J Neuroradiol 1996;17:143–150

Kaner T, Sasani M, Oktenoglu T, Solmaz B, Sarloglu AC, Ozer AF. Clinical analysis of 21 cases of spinal cord ependymoma: positive clinical results of gross total resection. J Korean Neurosurg Soc 2010;47:102–106

Raco A, Esposito V, Lenzi J, Piccirilli M, Delfini R, Cantore G. Long-term follow-up of intramedullary spinal cord ependymomas: a series of 202 cases. Neurosurgery 2005;56:972–981

Epstein FJ, Farmer JP, Freed D. Adult intramedullary spinal cord ependymomas: the result of surgery in 38 patients. J Neurosurg 1993;79:204–209

McGuire CS, Sainani KL, Fisher PG. Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer 2009;52:65–69

Hoshimaru M, Koyama T, Hashimoto N, Kikuchi H. Results of surgery for intramedullary spinal cord tumors: intermediate and long-term results in 51 patients. Neurosurgery 1989;25:855–859

Lin YH, Huang CI, Wong TT, et al. Treatment of spinal cord ependymomas by surgery with or without postoperative radiotherapy. J Neurooncol 2005;71:205–210

Kucia EJ, Bambakidis NC, Chang SW, Spetzler RF. Surgical technique and outcomes in the treatment of spinal cord ependymomas, part I: intramedullary ependymomas. Neurosurgery 2011;68(1, Suppl Operative):57–63; discussion 63

Burger P, Scheithauer B, Vogel F. Surgical Pathology of the Nervous System and Its Coverings. 3rd ed. New York: Churchill Livingstone; 1991

Wagle WA, Jaufman B, Mincy JE. Intradural extramedullary ependymoma: MR-pathologic correlation. J Comput Assist Tomogr 1988;12:705–707

Atlas S. Magnetic Resonance Imaging of the Brain and Spine. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1991

Fullbright R, Ross JS, Sze G. Application of contrast agents in MR imaging of the spine. J Magn Reson Imaging 1993;3:219–232

Goy AM, Pinto RS, Raghavendra BN, Epstein FJ, Kricheff II. Intradural extramedullary spinal cord tumors: MR imaging, with emphasis on associated cysts. Radiology 1986;161:381–386

Slasky BS, Bydder GM, Niendorf HP, Young IR. MR imaging with gadolinium-DTPA in the differentiation of tumor, syrinx, and cyst of the spinal cord. J Comput Assist Tomogr 1987;11:843–850

Brotchi J, Fischer G. Treatment. In: Fischer G, Brotchi J, eds. Intradural Extramedullary Spinal Cord Tumors. Stuttgart, Germany: Thieme; 1996;60–84

Froment J, Balériaux D, Turjman F, Patay Z, Rio F. Diagnosis: neuroradiology. In: Fischer G, Brotchi J, eds. Intradural Extramedullary Spinal Cord Tumors. Stuttgart, Germany: Thieme; 1996;33–52

White JB, Miller GM, Layton KF, Krauss WE. Nonenhancing tumors of the spinal cord. J Neurosurg Spine 2007;7:403–407

Nemoto Y, Inoue Y, Tashiro T, et al. Intramedullary spinal cord tumors: significance of associated hemorrhage at MR imaging. Radiology 1992;182:793–796

Djindjian M, Djindjian R, Houdart R, Hurth M. Subarachnoid hemorrhage due to intraspinal tumors. Surg Neurol 1978;9:223–229

Hawkins CP, Heron JR. Subarachnoid hemorrhage from spinal tumor (in the absence of spinal symptoms or signs). J Neurol Neurosurg Psychiatry 1988;51:305–307

Li MH, Holtas S. MR imaging of spinal intramedullary tumors. Acta Radiol 1991;32:505–513

Zimmerman RA, Bilaniuk LT. Imaging of tumors of the spinal canal and cord. Radiol Clin North Am 1988;26:965–1007

Lombardi G, Passerini A. Spinal Cord Disease: A Radiologic and Myelographic Analysis. Baltimore: Williams and Wilkins; 1964

Koeller KK, Sandberg GD; Armed Forces Institute of Pathology. From the archives of the AFIP. Cerebral intraventricular neoplasms: radiologic-pathologic correlation. Radiographics 2002;22:1473–1505

Fine MJ, Kricheff II, Freed D, Epstein FJ. Spinal cord ependymomas: MR imaging features. Radiology 1995;197:655–658

Barkovich AJ. Pediatric Neuroimaging. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005

Carr DH, Brown J, Bydder GM, et al. Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. AJR Am J Roentgenol 1984;143:215–224

Bydder GM, Brown J, Niendorf HP, Young IR. Enhancement of cervical intraspinal tumors in MR imaging with intravenous gadolinium-DTPA. J Comput Assist Tomogr 1985;9:847–851

Parizel PM, Balériaux D, Rodesch G, et al. Gd-DTPA-enhanced MR imaging of spinal tumors. AJR Am J Roentgenol 1989;152:1087–1096

Sze G, Stimac GK, Bartlett C, et al. Multicenter study of gadopen-tate dimeglumine as an MR contrast agent: evaluation in patients with spinal tumors. AJNR Am J Neuroradiol 1990;11:967–974

Balériaux D, Parizel P, Bank W. Intraspinale and intramedullary pathology. In: Manefle C, ed. Imaging of the Spine and Spinal Cord. New York: Raven Press; 1992

Brotchi J, Dewitte O, Levivier M, et al. A survey of 65 tumors within 51 patients with spinal tumors. AJNR Am J Neuroradiol 1991;12:501–507

Rothwell CI, Jaspan T, Worthington BS, Holland IM. Gadolinium-enhanced magnetic resonance imaging of spinal tumors. Br J Radiol 1989;62:1067–1074

Chamberlain MC, Sandy AD, Press GA. Spinal cord tumors: gadolinium-DTPA-enhanced MR imaging. Neuroimaging 1991;33:469–474

Frey I, Le Breton C, Lefkopoulos A, et al. Intradural extramedullary spinal canal secondary neoplasms: MR findings in 30 patients. Eur Radiol 1998;8:1187–1192

Rumboldt Z, Lambert I, Talan-Hranilovic J, Marjan D, Sajko T. Nonenhancing spinal subdural metastatic tumor. AJNR Am J Neuroradiol 2005;26:2406–2409

Schiff D, O’Neill BP. Intradural spinal cord metastases: clinical features and treatment outcome. Neurology 1996;47:906–912